H2020Doctoral network2016–2020

DEMO · Dementia modelling

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2016-09-01 → 2020-08-31
EU contribution
€853,452
Participants
3
Scheme
MSCA-ITN-EID

Lines connect the coordinator with its partners.

Results in brief

Dementia modelling

Dementia constitutes a major burden on society, both in monetary costs and the suffering of patients and relatives. Alzheimer’s disease (AD), the most common form of dementia, is one of the most devastating healthcare problems faced by western society. The prevalence increases with the average lifetime year by year, and in most countries the population is aging. Different types of dementia require different treatments. Cardiovascular treatments may, e.g., prevent or slow vascular dementia (VaD), which is the second most common type of dementia. There are currently no disease-modifying treatments for AD, despite numerous promising drugs in development. Another challenge is that many of the dementias have clinically similar presentations and may co-exist (as many as 50% of AD patients may have VaD as well), making clinical diagnosis challenging. However, signs of dementia-related pathology are measurable using biomarkers far before clinical presentation, and the various types of dementia have quite different pathological bases. The overall objective of the Dementia Modeling (DeMo) project is to develop new models for AD, VaD and mixed AD and VaD progression using, among others, novel imaging biomarkers of vascular pathology alongside already established AD imaging biomarkers. Such models enable identification and differentiation of at-risk subjects for effective treatment, and they can be used to assess disease progression for among others treatment monitorization. The project emphasizes the use of historically widely used MRI scan types to enable use of historical imaging data in modeling. Algorithms are simultaneously developed for (1) robust disease progression modeling, and for the underlying necessary brain imaging biomarkers of VaD to be measured at each time point and entered to the disease progression model; i.e., (2) white matter lesion imaging biomarkers and (3) vascular pathology imaging biomarkers. Three early stage researchers (ESRs) are trained while performing these three objectives (1-3) of the project.

Data: CORDIS, © European Union

Project objective

Dementia constitutes a major burden on society, both in monetary costs and the suffering of patients and their relatives. It comprises a number of diseases including Alzheimer’s disease (AD) and vascular dementia (VaD). In recent years, imaging biomarkers have been developed including measures of brain morphology (MRI T1), vascular pathologies (MRI T2*/FLAIR), white matter abnormalities (MRI DWI), perfusion (MRI ASL), glucose turnover (PET FDG), and accumulation of pathological proteins (PET PIB/AV45). Quantitative measures using these biomarkers in large cohort studies have the potential to model the pathological process of the disease. This proposal would create an innovative training network, in which early stage researchers will develop new computational imaging biomarkers, under the supervision of experienced researchers, for the purpose of modeling dementia etiology. One researcher will investigate quantification of vascular pathologies, another will develop quantitative measures of white matter abnormalities from structural MRI, and the final researcher will construct a quantitative model of disease etiology using a maximum-likelihood framework. The early stage researchers will be enrolled as PhD students at University College London (UCL) under the EPSRC Centre for Doctoral Training in Medical Imaging (CDT), which is based in Centre for Medical Image Computing (CMIC), with the Dementia Research Centre (DRC) being one of the main clinical collaborators for CDT studentships. However, they will spend the majority of time at the research facilities of Biomediq A/S, Copenhagen Denmark, where they will be exposed to industry and work under professional guidance.

Original text from CORDIS.

Participants

Links

Data: CORDIS, © European Union